116 related articles for article (PubMed ID: 23988768)
1. Prediction of relapse after discontinuation of infliximab therapy in severe sarcoidosis.
Vorselaars AD; Verwoerd A; van Moorsel CH; Keijsers RG; Rijkers GT; Grutters JC
Eur Respir J; 2014 Feb; 43(2):602-9. PubMed ID: 23988768
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of infliximab biosimilar Inflectra
Schimmelpennink MC; Vorselaars ADM; van Beek FT; Crommelin HA; Deneer VHM; Keijsers RGM; Veltkamp M
Respir Med; 2018 May; 138S():S7-S13. PubMed ID: 29496351
[TBL] [Abstract][Full Text] [Related]
3. 18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab.
Keijsers RG; Verzijlbergen JF; van Diepen DM; van den Bosch JM; Grutters JC
Sarcoidosis Vasc Diffuse Lung Dis; 2008 Dec; 25(2):143-9. PubMed ID: 19382534
[TBL] [Abstract][Full Text] [Related]
4. Predictors of relapse in patients with ulcerative colitis in remission after one-year of infliximab therapy.
Farkas K; Lakatos PL; Nagy F; Szepes Z; Miheller P; Papp M; Palatka K; Bálint A; Bor R; Wittmann T; Molnár T
Scand J Gastroenterol; 2013 Dec; 48(12):1394-8. PubMed ID: 24131338
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of infliximab in refractory FDG PET-positive sarcoidosis.
Vorselaars AD; Crommelin HA; Deneer VH; Meek B; Claessen AM; Keijsers RG; van Moorsel CH; Grutters JC
Eur Respir J; 2015 Jul; 46(1):175-85. PubMed ID: 25929955
[TBL] [Abstract][Full Text] [Related]
6. Clinical outcomes in sarcoidosis after cessation of infliximab treatment.
Panselinas E; Rodgers JK; Judson MA
Respirology; 2009 May; 14(4):522-8. PubMed ID: 19386069
[TBL] [Abstract][Full Text] [Related]
7. Correlation of spleen metabolism assessed by 18F-FDG PET with serum interleukin-2 receptor levels and other biomarkers in patients with untreated sarcoidosis.
Kalkanis A; Kalkanis D; Drougas D; Vavougios GD; Datseris I; Judson MA; Georgiou E
Nucl Med Commun; 2016 Mar; 37(3):273-7. PubMed ID: 26544095
[TBL] [Abstract][Full Text] [Related]
8. Circulating tumor cells and [18F]fluorodeoxyglucose positron emission tomography/computed tomography for outcome prediction in metastatic breast cancer.
De Giorgi U; Valero V; Rohren E; Dawood S; Ueno NT; Miller MC; Doyle GV; Jackson S; Andreopoulou E; Handy BC; Reuben JM; Fritsche HA; Macapinlac HA; Hortobagyi GN; Cristofanilli M
J Clin Oncol; 2009 Jul; 27(20):3303-11. PubMed ID: 19451443
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of adalimumab in sarcoidosis patients who developed intolerance to infliximab.
Crommelin HA; van der Burg LM; Vorselaars AD; Drent M; van Moorsel CH; Rijkers GT; Deneer VH; Grutters JC
Respir Med; 2016 Jun; 115():72-7. PubMed ID: 27215507
[TBL] [Abstract][Full Text] [Related]
10. Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped.
Louis E; Mary JY; Vernier-Massouille G; Grimaud JC; Bouhnik Y; Laharie D; Dupas JL; Pillant H; Picon L; Veyrac M; Flamant M; Savoye G; Jian R; Devos M; Porcher R; Paintaud G; Piver E; Colombel JF; Lemann M;
Gastroenterology; 2012 Jan; 142(1):63-70.e5; quiz e31. PubMed ID: 21945953
[TBL] [Abstract][Full Text] [Related]
11. Earlobe sarcoidosis.
Vorselaars AD; Keijsers RG; Grutters JC
Sarcoidosis Vasc Diffuse Lung Dis; 2012 Mar; 29(1):55-7. PubMed ID: 23311125
[TBL] [Abstract][Full Text] [Related]
12. Recurrence of uveitis after discontinuation of infliximab.
Shakoor A; Esterberg E; Acharya NR
Ocul Immunol Inflamm; 2014 Apr; 22(2):96-101. PubMed ID: 23876234
[TBL] [Abstract][Full Text] [Related]
13. Diagnostic and prognostic value of 18F-FDG PET/CT for patients with suspected recurrence from squamous cell carcinoma of the esophagus.
Guo H; Zhu H; Xi Y; Zhang B; Li L; Huang Y; Zhang J; Fu Z; Yang G; Yuan S; Yu J
J Nucl Med; 2007 Aug; 48(8):1251-8. PubMed ID: 17631554
[TBL] [Abstract][Full Text] [Related]
14. 18F-FDG PET, genotype-corrected ACE and sIL-2R in newly diagnosed sarcoidosis.
Keijsers RG; Verzijlbergen FJ; Oyen WJ; van den Bosch JM; Ruven HJ; van Velzen-Blad H; Grutters JC
Eur J Nucl Med Mol Imaging; 2009 Jul; 36(7):1131-7. PubMed ID: 19259660
[TBL] [Abstract][Full Text] [Related]
15. Outcome after discontinuation of infliximab in patients with inflammatory bowel disease in clinical remission: an observational Danish single center study.
Steenholdt C; Molazahi A; Ainsworth MA; Brynskov J; Østergaard Thomsen O; Seidelin JB
Scand J Gastroenterol; 2012 May; 47(5):518-27. PubMed ID: 22375898
[TBL] [Abstract][Full Text] [Related]
16. Prognostic value of dual-time-point 18F-fluorodeoxyglucose positron emission tomography in patients with pulmonary sarcoidosis.
Umeda Y; Demura Y; Morikawa M; Ameshima S; Tsuchida T; Fujibayashi Y; Okazawa H; Ishizaki T
Respirology; 2011 May; 16(4):713-20. PubMed ID: 21382131
[TBL] [Abstract][Full Text] [Related]
17. Role of FDG-PET/CT in evaluating surgical outcomes of operable breast cancer--usefulness for malignant grade of triple-negative breast cancer.
Ohara M; Shigematsu H; Tsutani Y; Emi A; Masumoto N; Ozaki S; Kadoya T; Okada M
Breast; 2013 Oct; 22(5):958-63. PubMed ID: 23756383
[TBL] [Abstract][Full Text] [Related]
18. Long term follow-up of infliximab efficacy in pulmonary and extra-pulmonary sarcoidosis refractory to conventional therapy.
Russell E; Luk F; Manocha S; Ho T; O'Connor C; Hussain H
Semin Arthritis Rheum; 2013 Aug; 43(1):119-24. PubMed ID: 23332903
[TBL] [Abstract][Full Text] [Related]
19. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
Markenson JA; Gibofsky A; Palmer WR; Keystone EC; Schiff MH; Feng J; Baumgartner SW
J Rheumatol; 2011 Jul; 38(7):1273-81. PubMed ID: 21572150
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of metabolic tumor volume and total lesion glycolysis from ¹⁸F-FDG PET/CT in patients undergoing stereotactic body radiation therapy for stage I non-small-cell lung cancer.
Vu CC; Matthews R; Kim B; Franceschi D; Bilfinger TV; Moore WH
Nucl Med Commun; 2013 Oct; 34(10):959-63. PubMed ID: 23921784
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
